Step 1 topics → Reproductive → Exogenous Androgens (Testosterone, Methyltestosterone)

Exogenous Androgens (Testosterone, Methyltestosterone)

USMLE Step 1 trap: Confuses exogenous testosterone's HPG suppression causing infertility with expected improvement in spermatogenesis. Exogenous testosterone suppresses LH and FSH via negative feedback, reducing intratesticular testosterone and causing azoospermia and infertility.

Exogenous androgens — including testosterone (injectable, transdermal, topical) and the oral 17α-alkylated form methyltestosterone — act as androgen receptor agonists used in hypogonadism replacement and, in abuse contexts, as anabolic agents. USMLE Step 1 tests this topic primarily through adverse effect recognition and mechanism application, not simple recall. The classic trap is assuming that giving testosterone to a hypogonadal man will restore fertility — it won't, and understanding why requires knowing how exogenous androgens interact with the HPG axis. The exam also distinguishes between formulations in a clinically meaningful way, particularly around hepatotoxicity.

The tricky parts cluster around two themes: HPG suppression consequences and route-dependent toxicity. Students often conflate 'restoring testosterone levels' with 'restoring testicular function,' but these are mechanistically opposite outcomes. Similarly, hepatotoxicity is not a class effect — it's specific to 17α-alkylated oral androgens like methyltestosterone, and the exam exploits students who generalize from one formulation to all androgens. Erythrocytosis is a frequently overlooked adverse effect that has downstream thrombotic implications worth knowing.

On USMLE Step 1, this concept appears most often in vignettes involving athletes using anabolic steroids, men on testosterone replacement presenting with lab abnormalities, or question stems asking you to predict the consequence of a given intervention on spermatogenesis or liver function. It's a low-yield topic overall, but the specific misconceptions here are high-yield traps that show up in the context of endocrine or reproductive pharmacology passages.

From real student decks
51%have cards covering this topic
38%have mature cards

Common misconceptions

Common mistake
Wrong: Exogenous testosterone supplementation improves spermatogenesis in hypogonadal men.
Right: Exogenous testosterone suppresses LH and FSH via negative feedback, reducing intratesticular testosterone and causing azoospermia and infertility.
Exogenous testosterone does raise serum testosterone levels, but it does so at the cost of suppressing LH and FSH through hypothalamic-pituitary negative feedback. Since spermatogenesis depends on high intratesticular testosterone driven by local LH-stimulated Leydig cell production — not circulating testosterone — exogenous dosing actually collapses intratesticular testosterone and leads to azoospermia. This is why testosterone is paradoxically being studied as a male contraceptive, and why men on TRT who want fertility are given FSH/LH analogs like clomiphene or hCG instead.
Common mistake
Wrong: All forms of exogenous androgens carry equal hepatotoxicity risk.
Right: 17α-alkylated oral androgens (e.g., methyltestosterone) are hepatotoxic and associated with peliosis hepatis and cholestasis, whereas injectable or transdermal testosterone does not carry this risk.
Hepatotoxicity is not a class effect of all androgens — it is specific to 17α-alkylated compounds like methyltestosterone because the alkyl group at the 17α position resists first-pass hepatic metabolism, causing the drug to accumulate in hepatocytes and induce cholestasis and peliosis hepatis. Injectable testosterone esters and transdermal testosterone bypass hepatic first-pass metabolism entirely, so they do not carry this risk. On the exam, if a question specifies oral androgen use and asks about liver findings, think 17α-alkylation.
Common mistake
Gap: Missing that androgen-induced erythrocytosis raises thrombotic risk and requires hematocrit monitoring
Exogenous androgens stimulate erythropoietin production, causing erythrocytosis that increases thrombotic risk and requires hematocrit monitoring.
Exogenous androgens stimulate renal erythropoietin (EPO) production, which drives increased red blood cell mass — this is erythrocytosis, not just a minor lab finding. The clinical consequence is increased blood viscosity and a real elevated risk of thromboembolic events including DVT, PE, and stroke. This is why patients on testosterone replacement therapy require periodic hematocrit monitoring, and elevated hematocrit is a reason to dose-reduce or temporarily hold therapy.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know that exogenous androgens work as androgen receptor agonists, understand the available routes of administration (injectable, transdermal, oral), and explain how exogenous testosterone suppresses LH and FSH via HPG negative feedback.
  2. Identify the appropriate clinical contexts for androgen use — primarily hypogonadism replacement — and recognize the patterns of misuse in anabolic steroid abuse scenarios.
  3. Predict and distinguish adverse effects by formulation: 17α-alkylated oral androgens (methyltestosterone) cause hepatotoxicity including peliosis hepatis and cholestasis; all exogenous androgens can cause erythrocytosis and infertility via HPG suppression; and androgen use can stimulate prostate tissue growth.

Can you avoid these mistakes?

A 28-year-old male bodybuilder has been self-administering high-dose testosterone injections for 18 months. He and his partner are now trying to conceive without success. Semen analysis shows azoospermia. What is the mechanism responsible for his infertility, and what would you expect his LH and FSH levels to be?
A 35-year-old man with hypogonadism is started on oral methyltestosterone. Three months later, labs show elevated bilirubin and alkaline phosphatase. What structural feature of methyltestosterone is responsible for this complication, and would you expect the same finding if he had been started on injectable testosterone enanthate instead?
A patient on long-term testosterone replacement therapy comes in for routine follow-up. His hematocrit is 54%. Why is this a concern, and what is the underlying mechanism by which testosterone caused this finding?
A physician wants to treat a hypogonadal man who also desires future fertility. Why is exogenous testosterone a poor choice for this patient, and what alternative agents could stimulate endogenous testosterone production without suppressing spermatogenesis?

Related topics

Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →